Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Vivoryon Therapeutics reduces costs, strengthens R&D focus and extends cash runway

Vivoryon Therapeutics reports sharply lower R&D and administrative expenses in Q3 2025, cutting the net loss from €17.1m in 2024 to €7.6m in 2025. A private placement raised €5.1m; cash stood at €2.5m at the end of September, securing liquidity into Q3 2026. The company is advancing varoglutamstat to prepare a Phase 2b study in diabetic kidney disease and is evaluating additional indications. Marcus Ilsfeld will become the new CFO; management sees positive potential in the clinical data but notes cash- and study-related risks. » More on de.investing.com
Vivoryon Therapeutics reduces Q2 loss, shares fall despite progress

Vivoryon Therapeutics cut its net loss in the second quarter to $5.5m (previous year $13.6m) and significantly reduced operating expenses, including R&D to €2.8m. Cash and cash equivalents stood at €4.8m and financing runway is stated through January 2026. A US patent for the lead product Varglutemstat was granted through 2044, and a phase-2b study for diabetic nephropathy is planned. The share nevertheless fell by around 6.3% to $1.60 and is approaching its 52-week low, indicating investor uncertainty. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Vivoryon Therapeutics has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Vivoryon Therapeutics had revenue of €0 and net profit of -€3.39m

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	-67k	-
Net profit	-3.39m	-
EBITDA	-3.32m	-

Fundamentals

Metric	Value
Market capitalization	€22.8m
Number of shares	29.61m
52-week high/low	€1.68 - €0.76
Dividends	No
Beta	1.45
P/E ratio	-3.39
PEG ratio	-0.05
P/B ratio	14.76
P/S ratio	0.00

Company profile

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.

Name	Vivoryon Therapeutics
CEO	Frank T. Weber
Headquarters	Halle, sa Germany
Website	vivoryon.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	10/10/2018
Employees	14